Single-agent chemotherapy for non-small cell lung cancer

The survival and quality of life benefits of combination chemotherapy in patients with non-small cell lung cancer (NSCLC) are now well recognized. Since many clinical trials have been conducted in relatively young patients with good performance status, many elderly patients and patients with poor performance status are not offered chemotherapy because of concerns about higher risks of toxicity. The newer agents, including topotecan, are active as single agents in NSCLC, achieving response rates of up to 30%. Overall survival and symptoms may be improved when these agents are added to best supportive care. They are well tolerated in both elderly patients and patients with poor performance status. The major toxicity with the standard 5-day administration schedule of topotecan is myelosuppression, but weekly schedules may offer reduced toxicity while maintaining efficacy. Thus, single-agent therapy with newer agents is generally considered in elderly and poor performance status patients. However, combination chemotherapy may also be appropriate for some patients in these subgroups. Future studies of chemotherapy in NSCLC should not exclude elderly patients and patients with poor performance status.